HER2-Positive Breast Cancer Demonstrates Heterogenous Outcomes
, March 8, 2011
The discovery of Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.
Genomic Profiles: Not Yet Ready for Full Time Use
, March 8, 2011
Are genomic profiles refined enough that they should be used routinely to determine which breast cancer patients should receive adjuvant therapy? According to J. Michael Dixon, MD, who will be presenting the contra argument to this question in a debate at the Miami Breast Cancer Conference this week, the answer is: Not yet.
Breast Imaging Pioneer Sheds Light on Screening Technology
October 6, 2010
It’s very important to carefully analyze the data and weigh the pros and cons and the risk to benefits that exist within any study. Naturally, because mammography is such a widely used screening tool, it gets quite a bit of scrutiny. But it is all about the data, how it’s sliced and diced. Unfortunately many studies are not ideally run.
Oncology EMRs: Buyer Beware, an Interview with Marty Neltner
July 12, 2010
Clinicians often cite enhanced quality care, patient safety, and increased efficiencies as rationale for implementing electronic medical records. Those are strong reasons for interest in medical software. However, in a climate where reimbursements are falling, the cost and difficulty of EMRs can increasingly seem to be a barrier.
Value in Oncology, an Interview with Marty Neltner
, June 8, 2010
In this exclusive CancerNetwork Blog podcast, nationally regarded healthcare specialist, Marty Neltner, talks about how given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume.
Targeted Therapies: A Paradigm Shift in RCC
Interviewed by Ron Piana
, June 8, 2010
Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.
New Generation of Targeted Therapies Show Promise in RCC
Andrew J. Armstrong, MD, ScM
, June 7, 2010
In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, addressed the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.
50 Shades of Pink—And Why It Helps to Know the Difference
Rebecca Bechhold, MD1
, May 17, 2013
Buy toxic chemicals and support breast cancer research! Not lying—just saw an ad on TV for weed killer and it had a pink ribbon logo on its packaging indicating, “A portion of every sale goes to support breast cancer research and awareness.” We have plenty of weed killer and a perfect lawn at our house, so I am no critic of the product. But have you noticed the pink ribbon logo on virtually every conceivable item or service?
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access Judy Capko,
May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.